| Prevalence | Approximately 20-35% of CBS patients demonstrate olfactory dysfunction on standardized testing (UPSIT < 15th percentile) |
| Severity | When present, olfactory deficits are typically mild to moderate, rarely reaching the severe range seen in DLB |
| Temporal Pattern | Olfactory loss may develop concurrently with or after motor symptoms; pre-motor olfactory loss is less characteristic than in PD |
| Anosmia | Complete anosmia is rare in CBS, occurring in fewer than 10% of affected individuals |
| Screening Tool | Olfactory testing (UPSIT, SS-16) can help differentiate CBS from PD when severe olfactory loss is present |
| Pathological Prediction | Preserved olfaction suggests non-Lewy body pathology |
| Complementary Biomarker | When combined with other markers (MRI, FDG-PET), olfactory testing adds diagnostic confidence |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!